Bone Marker-directed Dosing of ZOMETA® (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma.
Bone Marker-directed Dosing of ZOMETA® (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma.
This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to two years.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Miami Shores, Florida 33138, United States
Orange Park, Florida 32073, United States
Maywood, Illinois 60153, United States
Clinton, Maryland 20735, United States
Boston, Massachusetts 02115, United States
Omaha, Nebraska 68122-1799, United States
Somerset, New Jersey 08873, United States
Rochester, New York 14621, United States
Rochester, New York 14642, United States
Syracuse, New York 13210, United States
Mt. Pleasant, South Carolina 29464, United States